



SUMMARY OF PROPOSED AMENDMENTS TO RULES PERTAINING TO THE LIST OF CONTROLLED SUBSTANCES FOR THE STATE OF ARKANSAS

The proposed listed amendments update List of Controlled Substances to include these drugs.

- 1) Meta-fluorofentanyl [other name(s): *N*-(3-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)propionamide]. The DEA has placed this opioid analgesic into Schedule I because it has no recognized medical use. This drug would be included as Schedule I to follow DEA. Page 5, Schedule I, (b), (51), (vi), (RR).
- 2) Meta-fluoroisobutyl fentanyl [other name(s): *N*-(3-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)isobutyramide]. The DEA has placed this opioid analgesic into Schedule I because it has no recognized medical use. This drug would be included as Schedule I to follow DEA. Page 5, Schedule I, (b), (51), (vi), (SS).
- 3) Para-methoxyfuranyl fentanyl [other name(s): *N*-(4-methoxyphenyl)-*N*-(1-phenethylpiperidin-4-yl)furan-2-carboxamide]. The DEA has placed this opioid analgesic into Schedule I because it has no recognized medical use. This drug would be included as Schedule I to follow DEA. Page 5, Schedule I, (b), (51), (vi), (TT).
- 4) Para-methylcyclopropyl fentanyl [other name(s): *N*-(4-methylphenyl)-*N*-(1-phenethylpiperidin-4-yl)cyclopropanecarboxamide]. The DEA has placed this opioid analgesic into Schedule I because it has no recognized medical use. This drug would be included as Schedule I to follow DEA. Page 5, Schedule I, (b), (51), (vi), (UU).
- 5) 3-furanyl fentanyl [other name(s): *N*-(1-phenethylpiperidin-4-yl)-*N*-phenylfuran-3-carboxamide]. The DEA has placed this opioid analgesic into Schedule I because it has no recognized medical use. This drug would be included as Schedule I to follow DEA. Page 5, Schedule I, (b), (51), (vi), (VV).
- 6) 2',5'-dimethoxyfentanyl [other name(s): *N*-(1-(2,5-dimethoxyphenethyl)piperidin-4-yl)-*N*-phenylpropionamide]. The DEA has placed this opioid analgesic into Schedule I because it has no recognized medical use. This drug would be included as Schedule I to follow DEA. Page 5, Schedule I, (b), (51), (vi), (WW).
- 7) Isovaleryl fentanyl [other name(s): 3-methyl-*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylbutanamide]. The DEA has placed this opioid analgesic into Schedule I because it has no recognized medical use. This drug would be included as Schedule I to follow DEA. Page 5, Schedule I, (b), (51), (vi), (XX).



- 8) Ortho-fluorofuranyl fentanyl [other name(s): *N*-(2-fluorophenyl)-*N*-(1-phenethylpiperidin-4-yl)furan-2-carboxamide. The DEA has placed this opioid analgesic into Schedule I because it has no recognized medical use. This drug would be included as Schedule I to follow DEA. Page 6, Schedule I, (b), (51), (vi), (YY).
- 9) Alpha'-methyl butyryl fentanyl [other name(s): 2-methyl-*N*-(1-phenethylpiperidin-4-yl)-*N*-phenylbutanamide]. The DEA has placed this opioid analgesic into Schedule I because it has no recognized medical use. This drug would be included as Schedule I to follow DEA. Page 6, Schedule I, (b), (51), (vi), (ZZ).
- 10) Etodesnitazene [other name(s): Etazene], *N*-Pyrrolidino Etonitazene (other name(s) Etonitazepyne), and Protonitazene are Schedule I controlled substances. To follow DEA, controlled substance code numbers have been set forth opposite of these substances. Page 6, Schedule I, (b), (54), (vi), (E), Page 6, Schedule I, (b), (54), (vi), (O), and Page 6, Schedule I, (b), (54), (vi), (Q).
- 11) 2-Methyl AP-237. [other name(s): 1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one]. The DEA has placed this synthetic opioid into Schedule I because it has no recognized medical use. This drug would be included as Schedule I to follow DEA. Page 7, Schedule I, (b), (55).
- 12) 3-methylmethcathinone (other names: 3-MMC). The DEA has identified this synthetic cathinone as a positional isomer of mephedrone a currently listed controlled substance. This drug without a recognized medical use would be included as Schedule I with subsequent numbering changes to follow. Page 13, Schedule I, (f), (2), (xvii).
- 13) 4-methyl-1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one [other names: *alpha*-PiHP, and Alpha-Pyrrolidinoisohexanophenone). The DEA has identified this synthetic cathinone as a positional isomer of Alpha-PHP a currently listed controlled substance. This drug without a recognized medical use would be included as Schedule I. Page 14, Schedule I, (f), (2), (xxviii).
- 14) The following items are marked for clean up:
 - a. Page 2, Schedule I, (b), (46);
 - b. Page 3, Schedule I, (b), (51), (vi), (B);
 - c. Page 3, Schedule I, (b), (51), (vi), (C);
 - d. Page 3, Schedule I, (b), (51), (vi), (G);
 - e. Page 3, Schedule I, (b), (51), (vi), (I);
 - f. Page 4, Schedule I, (b), (51), (vi), (N);
 - g. Page 12, Schedule I, (f), (1), (iv);
 - h. Page 12, Schedule I, (f), (1), (ix);
 - i. Page 12, Schedule I, (f), (1), (xi);
 - j. Page 13, Schedule I, (f), (2), (iii);
 - k. Page 17. Schedule II, (d), (3);
 - l. Page 19, Schedule III, (c), (13);



- m. Page 23, Schedule III, (g), (51); and
- n. Page 27, Schedule IV, (d), (1).

15) Xylazine The potential adverse health effects when abused, and increasing national prevalence of xylazine utilized as an adulterating agent to other illicit substances poses a threat to public health and safety. The substance will be included as a Schedule III controlled substance, Page 19, Schedule III, (c), (15), (i through vi), with outlined exceptions utilizing the following language:

Xylazine and any material, compound, mixture, or preparation which contains any quantity of xylazine, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation, except in the following uses:

- i) Dispensing, prescribing, or administering, to an animal, a drug containing xylazine that has been approved by the United States Secretary of Health and Human Services under section 512 of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 360b);
- ii) Dispensing, prescribing, or administering xylazine to an animal that is permissible under section 512 (a)(4) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 360b(a)(4));
- iii) Possessing a drug containing xylazine, as described in this Section (15), for animal use:
 - (A). By a licensed pharmacist or licensed veterinarian; or
 - (B). Pursuant to a valid prescription from a licensed veterinarian.
- iv) Possessing, manufacturing, distributing, or using xylazine as an active pharmaceutical ingredient for manufacturing an animal drug either:
 - (A). Approved under section 512 of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 360b); or
 - (B). Issued an investigation use exemption under section 512 of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 360b(j));
- v) Manufacturing, distributing, or using a xylazine bulk chemical for pharmaceutical compounding by a licensed pharmacist or veterinarian; or
- vi) Another use approved or permissible under the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 301, et seq.) or under 21 CFR Part 530, Subpart B.

16) Zuranolone. The FDA approved this drug for use in treatment of post-partum depression. This drug would be included as Schedule IV to follow DEA. Page 27, Schedule IV, (c), (61).



- 17) ADB-BUTINACA or *N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1*H*-indazole-3-carboxamide. The DEA has identified this synthetic cannabinoid as positional isomer of AB-PINACA, a currently listed controlled substance. This drug without a recognized medical use would be included as Schedule VI. Page 36, Schedule VI, (a), (5), (xi), (LL).